| Document |
Document Title |
|
JP2505313B2 |
Disclosed is a method for enhancing the production of T cell lymphokines, which comprises exposing T cell lymphocytes which have a potential to make selected T cell lymphokines to an appropriate concentration of at least one particular s...
|
|
JPH08503471A |
Invented are 17 alpha and 17 beta -substituted acyl-3-carboxy-3,5-diene analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5- alpha...
|
|
JPH0892097A |
PURPOSE: To obtain a topical antifungal/corticosteroid composition containing each specific fungicide and anti-inflammatory steroid in a vehicle, excellent in fungi proliferation inhibitory action and anti-inflammatory action, and capabl...
|
|
JPH0881492A |
To profitably obtain the subject derivative useful as an intermediate for synthesizing steroid compounds and so on through several kinds of intermediates comprising new compounds by allowing a 17-keto-steroid derivative to react with a h...
|
|
JPH0826062B2 |
9-Alpha-hydroxy- steroids (I) contg. a D-ring of formula (A) are new; R2 = ethynyl (provided R5 is not acetoxy if R4 = H), haloethynyl, opt. protected OH, cyano, 1'-Ra-ethenyl; or 1',1'-trimethylene dithio-ethyl; Ra = 1-6C alkoxy or alky...
|
|
JPH0859473A |
PURPOSE: To provide a cranial nerve cell protecting agent containing a specific compound as an active component, effective for remarkably suppressing the death of nerve cell induced by glutamic acid, having cranial nerve cell protecting ...
|
|
JPH08501552A |
A method and compound having hydrocortisone and tretinoin is disclosed for the treatment of hair loss. The method also includes identifying any underlying conditions causing hair loss, treating the underlying conditions if possible, admi...
|
|
JPH08500821A |
Invented are 17 alpha and 17 beta -alkylketone-3-carboxy aromatic A ring analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5- alph...
|
|
JPH085910B2 |
Process for the production of a DELTA <17(20)>-steroid of formula (II) which comprises starting with a 16-unsaturated corticoid of formula (I) and contacting the 16-unsaturated corticoid (I) with a methylating agent in the presence of a ...
|
|
JPH07116215B2 |
Steroid derivatives represented by formula (I) are disclosed. wherein R is a hydrogen atom, a halogen atom, a hydroxy group, or a group -OCOR1, wherein R1 is a linear or branched alkyl group which may be substituted by a halogen atom or ...
|
|
JPH07116222B2 |
A process for preparing 21-desoxyprednisolone 17-esters of formula (IV) is disclosed. The process comprises reacting a prednisolone 17 alpha ,21-cyclic orthoester with an acid in a 40-60% lower alcohol solution to produce a prednisolone ...
|
|
JPH07316189A |
PURPOSE: To efficiently obtain the subject new compound usable as a raw material for anti-hypertensive agents by oxidizing and then reducing the unsaturated lactone ring of digitoxigenin-3-acetate with a periodate in the presence of ruth...
|
|
JPH07278180A |
PURPOSE: To provide new compounds having strong affinity to sigma acceptor and activity against the interpenetration of calcium into sperms and especially useful as male contraceptives. CONSTITUTION: The objective steroids are represente...
|
|
JPH0794395B2 |
|
|
JPH07247215A |
PURPOSE: To obtain a therapeutic agent for treating granulomatous and fibromatous lung disease without any adverse effect by containing an active component of known pentoxifylline as a vasodilator, or further adding an additive therapeut...
|
|
JPH0780900B2 |
The invention refers to compounds having activity against inflammatory, allergic, and dermatological conditions. The compounds are characterized by the formula or a stereoisomeric component thereof, in which formula R1 is selected from a...
|
|
JPH0772193B2 |
A novel steroid of the formula I wherein X is methylene and R is an optionally substituted carbocyclic aryl or heterocyclic aryl or optionally substituted vinyl or ethynyl or X is a simple bond or -S- and R is optionally substituted carb...
|
|
JPH07506363A |
PCT No. PCT/US93/03778 Sec. 371 Date Oct. 28, 1994 Sec. 102(e) Date Oct. 28, 1994 PCT Filed Apr. 22, 1993 PCT Pub. No. WO93/22333 PCT Pub. Date Nov. 11, 1993Invented are 17 alpha and 17 beta -substituted acyl-3-carboxy aromatic A ring an...
|
|
JPH0762028B2 |
The invention refers to compounds having anti- inflammetory activity characterized by the formulaor a stereoisomeric component thereof, in which formula the 1,2-position is saturated or is a double bandX, is selected from hydrogen, fluor...
|
|
JPH0753750B2 |
The invention provides novel pregnane derivatives having the formula: wherein X = F, Cl or Br; R1 = F or Cl; R2 = H( beta OH) or O; R3 = alkyl(1-4 C); R4 = alkyl(1-4 C); and the dotted line indicates the optional presence of a double bon...
|
|
JPH0745511B2 |
Compounds of formula (I) : in which, inter alia, R<1> is H or C1-8alkyl and M is O or S, processes for their preparation, pharmaceutical compositions containing then and their use as inhibitors of 5- alpha -reductase in the treatment in ...
|
|
JPH07503466A |
PCT No. PCT/US93/00211 Sec. 371 Date Jul. 25, 1994 Sec. 102(e) Date Jul. 25, 1994 PCT Filed Jan. 26, 1993 PCT Pub. No. WO93/15103 PCT Pub. Date Aug. 5, 1993.Novel steroids having a 9 alpha -hydroxy or a 9 alpha -carbonate substituent can...
|
|
JPH0725679B2 |
Pharmaceutical compositions comprising tetrahydrocortisol and a method of using it in the control of intraocular pressure are disclosed.
|
|
JPH0714880B2 |
PCT No. PCT/GB85/00588 Sec. 371 Date Aug. 18, 1986 Sec. 102(e) Date Aug. 18, 1986 PCT Filed Dec. 16, 1985 PCT Pub. No. WO86/03749 PCT Pub. Date Jul. 3, 1986.A method for preparing a stable aerosol formulation of beclomethasone dipropiona...
|
|
JPH0710877B2 |
Known pregnane derivatives are prepared by esterificiation of known androstane derivatives to give new ester of Formula III (III) wherein in each case symbolizes a single bond or a double bond, n is 1 or 2, R1 is hydrogen or methyl, R2 i...
|
|
JPH07500086A |
(57) [Summary] Since this publication is application data before electronic filing, summary data is not recorded.
|
|
JPH06104679B2 |
The invention relates to DELTA <1><4>-16 alpha ,17-dihydroxypregnane derivatives of general formula (I), wherein A represents a hydrogen atom, or hydroxyl or trifluoroacetoxy group; X represents a hydrogen or halogen atom with the provis...
|
|
JPH06510982A |
Compounds are provided which are highly selective inhibitors of the cytochrome P-450C17, commonly known as 17,20-lyase enzyme, responsible for androgen biosynthesis. These compounds can be administered to patients to inhibit the producti...
|
|
JPH0699470B2 |
The invention relates to a new process for the preparation of 21-hydroxy-20-keto-steroids from 17-(isocyano-sulfonylmethylene)-steroids whereby simultaneously an unsaturated bond is introduced between C16 and C17. Furthermore the inventi...
|
|
JPH0689021B2 |
Perchloryl fluoride when reacted with the appropriately protected 9 alpha -hydroxyandrostenedione stereoselectively produces the corresponding 6 beta -fluoro steroid.
|
|
JPH0686477B2 |
|
|
JPH06509108A |
In the field of organic chemistry, and therapeutical chemistry in particular, 6-substituted 19-nor pregnanes are provided which are selected from the group consisting of 6-substituted 3-keto-$g(D)4-19-nor-pregnenes having partial formula...
|
|
JPH0653756B2 |
17-Substituted-21-hydroxy or 21-acylated steroids are prepared from 20-enol steroids in two steps, the first comprising reaction with peroxymonosulfate ion in a biphasic phase-transfer-catalysed medium (which can give novel 20,21-epoxy-c...
|
|
JPH06505958A |
Method, compositions, and compounds for modulating brain excitability to alleviate stress, anxiety, and seizure activity using certain steroid derivatives that act at a newly identified site on the gamma-ammobutyric acid/benzodiazepine r...
|
|
JPH0649717B2 |
The intermediate products of formula (II): R' = especially H or optionally substituted alkyl, alkenyl, alkynyl, aryl or aralkyl, hydroxyl, tetrahydropyranyl, tert-butoxy, optionally esterified carboxyl, amino, mono- or dialkylamino, trit...
|
|
JPH0647543B2 |
The process consists in dissolving a corticosteroid in the lipid phase of nonionic amphiphilic lipid vesicles consisting of one or more lipid lamellae. Composition for carrying out the above process, in which the vesicles are dispersed i...
|
|
JPH06505232A |
PCT No. PCT/SE92/00055 Sec. 371 Date Aug. 31, 1993 Sec. 102(e) Date Aug. 31, 1993 PCT Filed Jan. 29, 1992 PCT Pub. No. WO92/13872 PCT Pub. Date Aug. 20, 1992Disclosed are the 22R and 22S epimers of compounds of the formula wherein X1 rep...
|
|
JPH0634749B2 |
A method for preparing 11 beta , 17 alpha , 20, 21-tetrahydroxy steroids of the pregnane class comprises incubating the corresponding 17 alpha , 20 alpha or beta , 21-trihydroxy steroid in the presence of a culture medium capable of effe...
|
|
JPH0633287B2 |
|
|
JPH0641187A |
PURPOSE: To produce a new compd. having excellent local antiinflammatory action, showing good local to systemic antiinflammatory activity and useful as agents for treating inflammatory and allergic dermatosis. CONSTITUTION: The compd. of...
|
|
JPH0586768B2 |
|
|
JPH05508409A |
PCT No. PCT/DK91/00172 Sec. 371 Date Jan. 11, 1993 Sec. 102(e) Date Jan. 11, 1993 PCT Filed Jun. 24, 1991 PCT Pub. No. WO92/01454 PCT Pub. Date Feb. 6, 1992.The present invention relates to the use of 20(R)-22-oxavitamin D analogues for ...
|
|
JPH05507912A |
Novel angiostatic DELTA <4,9(11)>-steroids (I), C21-oxygenated steroids (II) and other known steroidal compounds have been found to be useful in treating angiogenesis in mammals who have a need for the same. These steroids are useful in ...
|
|
JPH0564158B2 |
6 alpha ,16 beta -Dimethyl corticoids of general Formula I (I) wherein the bond ----is a single bond or a double bond, and X is a hydrogen atom, a fluorine atom, a chlorine atom, or a bromine atom, Z is a hydrogen atom or, jointly with X...
|
|
JPH0559919B2 |
6 alpha ,16 alpha -Dimethyl corticoids of general Formula I (I) wherein the bond is a single bond or a double bond, X is a hydrogen atom, a fluorine atom, a chlorine atom, or a bromine atom, R1 is a formyl group, an alkanoyl group or alk...
|
|
JPH05178883A |
PURPOSE: To obtain a cyclodextrin clathrate complex of catechol estrogen and a peroxylipid inhibitor containing the clathrate complex as an active ingredient. CONSTITUTION: The objective catechol estrogen expressed by the formula (R1 is ...
|
|
JPH0544959B2 |
17-Substituted-21-hydroxy or 21-acylated steroids are prepared from 20-enol steroids in two steps, the first comprising reaction with peroxymonosulfate ion in a biphasic phase-transfer-catalysed medium (which can give novel 20,21-epoxy-c...
|
|
JPH0541637B2 |
|
|
JPH05132498A |
PURPOSE: To obtain the subject compound of a prodrug type manifesting high antiinflammatory action with a small dose. CONSTITUTION: The subject compound is a monoester or diester of a steroid which bears OH groups in the 11, 17 and 21 po...
|
|
JPH0533235B2 |
Novel corticoid 17 alpha -alkoxycarbonyl carboxylate derivatives are disclosed. These derivatives have strong topical anti-inflammatory activity and extremely weak systemic adverse reactions and are useful for the treatment of acute and ...
|
